CN Patent

CN109640987B — Menin-mll的桥联双环抑制剂及使用方法

Assigned to Kura Oncology Inc · Expires 2022-12-02 · 3y expired

What this patent protects

本发明提供抑制menin与MLL1、MLL2及MLL‑融合致癌蛋白的相互作用的方法。该方法可用于治疗白血病、实体癌、糖尿病及依赖于MLL1、MLL2、MLL融合蛋白和/或menin的活性之其他疾病。本发明亦提供用于该方法中的组合物。

USPTO Abstract

本发明提供抑制menin与MLL1、MLL2及MLL‑融合致癌蛋白的相互作用的方法。该方法可用于治疗白血病、实体癌、糖尿病及依赖于MLL1、MLL2、MLL融合蛋白和/或menin的活性之其他疾病。本发明亦提供用于该方法中的组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN109640987B
Jurisdiction
CN
Classification
—
Expires
2022-12-02
Drug substance claim
No
Drug product claim
No
Assignee
Kura Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.